Details of the Drug Combination

General Information of Drug Combination (ID: DCUFS33)

Drug Combination Name
MK-5108 SCH-900776
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs MK-5108   DMFGYKS SCH-900776   DM67EMK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: CAOV3
Zero Interaction Potency (ZIP) Score: 0.07
Bliss Independence Score: 0.34
Loewe Additivity Score: 1.97
LHighest Single Agent (HSA) Score: 7.48

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-5108
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
MK-5108 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aurora kinase B (AURKB) TT5LS6T AURKB_HUMAN Inhibitor [4]
Aurora kinase A (AURKA) TTPS3C0 AURKA_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of SCH-900776
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
SCH-900776 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Breast and ovarian cancer syndrome DC2MX6C UWB1289+BRCA1 Investigative [6]
Carcinoma DCWYU7K EFM192B Investigative [6]
Adenocarcinoma DCBWXWD OVCAR3 Investigative [1]
Adenocarcinoma DCGAT18 A427 Investigative [1]
Adenocarcinoma DC8TA85 NCIH23 Investigative [1]
Adenocarcinoma DC7Q4W3 HCT116 Investigative [1]
Germ cell tumour DCUJWM8 PA1 Investigative [1]
Malignant melanoma DCDW1MY A375 Investigative [1]
Malignant melanoma DCSRLNB RPMI7951 Investigative [1]
Malignant melanoma DCPZPWL SKMEL30 Investigative [1]
Ovarian endometrioid adenocarcinoma DCHU1F9 A2780 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00543387) Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001 AM4). U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7943).
4 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
5 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
6 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.